Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

LONDON, Nov 5 (Reuters) - Wegovy maker Novo Nordisk said on Wednesday that its executive vice president in charge of manufacturing was stepping down. Henrik Wulff, executive vice president of CMC and ...

Viking Therapeutics. Naturally, such activity raises the question as to who's next? And who might be next in line for a bid ...

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish ...

Novo Nordisk CEO Mike Doustdar tells CNBC he expects to close the company's takeover offer for Metsera. This as the company ...

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...

The pan-European Stoxx 600 index was down 0.4% shortly after the opening bell, with most major bourses and sectors trading in ...

To read yesterday’s edition of Five things for pharma marketers to know, click here.

Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a ...

BAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on Wednesday reported third-quarter earnings of $3.13 billion. The Bagsvaerd, Denmark-based company said it had profit of 70 ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...